Orano Med’s Post

On World Lung Cancer Day, we stand with everyone affected by lung cancer, emphasizing the importance of research, early detection, and availability of novel treatments for better patient outcomes. We are investigating our hexavalent OX40 agonist, #INBRX106, in Non-Small Cell Lung Cancer (NSCLC) in our actively enrolling Phase 1 study. Inhibrx is committed to advancing research in lung cancer in the hopes of identifying potential new treatment options. Learn more about our actively enrolling clinical trial here: https://bit.ly/49ZyYks #Inhibrx #BioTechnology

An exciting breakthrough step forward in early and easy detection of lung cancer, which kills more men and women each year than any other cancer! In cancer, it’s almost always about early detection, and this test appears to help! Looking forward to this test becoming mainstream, and Delfi moving on to develop other early detection cancer tests! Go Delfi!

Remember when we posted last week about how important both your detection and concentration methods are for low concentration samples? Liquid biopsies are the perfect example that require the highest performing workflows for detecting cancer mutations such as KRAS. Get the most out of your cancer research samples by combining our ultrasensitive oncology assays with the Ceres NEAT Biopsy Kit. Request our App Notes or this one from Ceres Nanosciences and learn more here: https://lnkd.in/eiv9xThW   #CeresNeat #GTMolecular #KRASdetection #CancerResearch #LiquidBiopsy #PCR #dPCR #digitalPCR #QIAcuity Ceres Nanosciences, Inc. QIAGEN Research use only. Not intended for diagnostic purposes.

🔬 Insights from ASCO 2024! Prof Piotr Wysocki from Jagiellonian University presents a subgroup analysis from the DESTINY-Pan Tumor 02 study. The study evaluates T-DXd in HER2-expressing urothelial cancer, showing promising response rates and progression-free survival benefits. Discover the potential of T-DXd as a novel treatment option in advanced urothelial cancer. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #UrothelialCancer #OncologyInnovation #DESTINYPanTumor02

🎙️ Dr. Meera Ragavan, our lung cancer subject matter expert, on precision in clinical trial matching: “There isn't a one-size-fits-all approach for matching patients to trials... For lung cancer patients, molecular testing is critical.” Dr. Ragavan highlights how Trial Library's platform tailors its approach to each cancer type, ensuring the most relevant criteria are prioritized in the matching process. This precision is revolutionizing the way we connect lung cancer patients with potentially life-changing clinical trials. Search trials now https://lnkd.in/e_BxWZUh #LungCancer #ClinicalTrials #PrecisionMedicine #OncologyInnovation

ASCO, 2024 Abstract Title: YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in human phase I trial

Genelux is making significant progress in reaching key milestones with Olvi-Vec. We anticipate commencing our Phase 2 Trial for Non-Small Cell Lung Cancer in the first half of this year, with the readout for our Phase 1 Trial for Small Cell Lung Cancer expected in the second half of the year. These trials mark a notable advancement in oncolytic therapy as they involve systemic (intravenous) administration. Concurrently, we are conducting our OnPrime/GOG-3076 Phase 3 trial through the regional route for Platinum-resistant/refractory Ovarian cancer, with an expected readout in 2025. #Stage4NeedsMore #DrugResearch #Nasdaq #HealthcareInvesting #BiotechInnovation

Your Research, Your Way: Crafting Customized Biosamples for Breakthrough Discoveries. *The researchers studying breast cancer have the autonomy to shape their research approach with us at The Biospecimen. *When it comes to breast cancer sample availability, the customization of biosamples is tailored to suit the researcher's preferences and needs. *The focus is on providing the necessary resources for breakthrough discoveries in breast cancer research, empowering researchers to conduct studies in a way that aligns with their unique vision and objectives. To know more visit www.thebiospecimen.com #breastcancer #researchanddevelopment #biosamples #biobanking

Did you know ProstateNow provides valuable insights into determining a patient's risk and potential treatment plans? Learn more about our ProstateNow germline test at the 2024 AUA Annual Meeting in San Antonio, TX between May 3-6! Our team will be in the exhibit hall sharing the transformative potential of ProstateNow, so stop swing by booth 823 and learn how our panel is assessing the risk of developing prostate cancer, assessing prognosis for localized prostate cancer, and how it can predict therapeutic responses for advanced prostate cancer. #AUA24

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting https://lnkd.in/gueE8eKE Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer [...]